Dacula, Sittie Alisha A.

HRN: 21-57-61  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/19/2022
AMPICILLIN 250MG (VIAL)
08/19/2022
08/26/2022
IVTT
150mg
Q12h
Psnb
Waiting Final Action 
08/19/2022
CEFOTAXIME 500MG (VIAL)
08/19/2022
08/26/2022
IVTT
150mg
Q12
Psnb
Waiting Final Action 
08/20/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/20/2022
08/20/2022
IVT
30mg
As Loading Dose
T/C Necrotizing Enterocolitis
Waiting Final Action 
08/20/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
08/20/2022
08/26/2022
IVT
15mg
Q8
T/C Necrotizing Enterocolitis
Waiting Final Action 
08/20/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
08/20/2022
08/27/2022
IVTT
200mg
Q8
NEC
Waiting Final Action 
08/21/2022
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
08/21/2022
08/31/2022
IV
16mg
Q48hrs
NEC
Waiting Final Action 
08/25/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
08/25/2022
08/31/2022
IV
30mg
OD
Necrotizing Enterocolitis
Waiting Final Action 
08/26/2022
CEFOTAXIME 500MG (VIAL)
08/26/2022
09/02/2022
IV
60mg
Q8h
T/c Sepsis Neonatorum
Waiting Final Action 
08/26/2022
OXACILLIN 500MG (VIAL)
08/26/2022
09/02/2022
IV
100mg
Q6h
T/c Sepsis Neonatorum
Waiting Final Action 
08/26/2022
CEFTAZIDIME 1GM (VIAL)
08/26/2022
09/02/2022
IV
60mg
Q8h
T/c Sepsis Neonatorum
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: